Sun Pharma plans INR 150 billion debt issue: what it means for Sun Pharma stock

Published on 10/09/2026 at 11:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q1 fiscal 2027 revenue reached INR 153.00 billion, up 10.10 percent. For Sun Pharma stock, this means INR 4.2 trillion market value.

Sun Pharma announced a proposed INR 150.0 billion non-convertible debenture issue for October 12, 2026.
Q1 fiscal 2027 revenue reached INR 153.0 billion, up 10.10 percent year over year.
The company reported FY26 revenue of INR 582.0 billion and an EBITDA margin of 30.30 percent.
Sun Pharma stock had a market capitalization of INR 4.2 trillion as of October 9, 2026.

Sun Pharma, INE044A01036, Illustration mit AI erstellt.

Sun Pharma (ISIN INE044A01036) had announced on October 7, 2026, that its board would consider issuing up to INR 150.00 billion of listed, rated, unsecured and redeemable non-convertible debentures. According to ScanX on October 7, 2026, the securities would be issued through private placement in one or more tranches. The proposal gives Sun Pharma stock a financing story alongside the company's latest operating figures.

Three events shaped the story

On September 22, 2026, Sun Pharma presented FY26 revenue of INR 582.00 billion and an EBITDA margin of 30.30 percent, according to StockFin. On October 1, 2026, the company announced LEQSELVI data showing 93.90 percent response maintenance at Week 108. The October 7, 2026, debenture proposal was the latest of the three events and set the possible issue size at INR 150.00 billion.

What does the debt plan mean?

The proposed ceiling equals 25.77 percent of FY26 revenue, calculated from INR 150.00 billion divided by INR 582.00 billion. The issue is proposed as unsecured and redeemable debt, so the eventual terms, coupon and use of proceeds will determine its effect on financing costs and leverage. The October 12 board meeting is the decision point, rather than a completed issuance.

Growth remains the counterweight

Sun Pharma's latest reported quarter provides the operating counterweight. In the first quarter of fiscal 2027, revenue was INR 153.00 billion and net income was INR 28.95 billion, according to StockFin. Revenue increased 10.10 percent from the year-earlier quarter, while the reported figures included INR 1.62 billion of Organon acquisition-related costs.

Dates for the next decision

The next dated event is October 12, 2026, when the board is scheduled to consider the debenture proposal, as listed by NSE India. The same exchange page identifies Sun Pharmaceutical Industries Limited under ticker SUNPHARMA, lists the company in the NIFTY 50 and classifies it in pharmaceuticals.

Market value and exchange context

Sun Pharma had a market capitalization of INR 4.2 trillion as of October 9, 2026. Its NSE quote was INR 1,760.00 at 3:15 p.m. IST on October 9, 2026, with the exchange session open; the quote was up INR 0.20, or 0.01 percent, from INR 1,759.80. The proposed debt ceiling and the 10.10 percent revenue increase place capital allocation beside continuing operating growth.